Melanotan-1 vs MT-1 — Same Peptide, Different Names

The search for what's the difference between melanotan-1 and mt-1 returns zero meaningful distinctions because there are none. MT-1 is the abbreviated research designation for Melanotan-1, which is itself the developmental name for afamelanotide. A 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). The naming confusion predates widespread clinical awareness: MT-1 was coined during early peptide synthesis protocols at the University of Arizona in the 1980s, long before the compound entered formal clinical trials under the afamelanotide designation. If you're comparing MT-1 and Melanotan-1 expecting to choose between two peptides, you're comparing a compound to itself.

Our team works directly with researchers sourcing peptides for photoprotection and melanogenesis studies. The question surfaces repeatedly. And the answer matters because misunderstanding nomenclature creates procurement errors, dosing confusion, and incorrect experimental design.

What's the difference between Melanotan-1 and MT-1?

There is no difference. Melanotan-1 and MT-1 are identical designations for the same synthetic peptide, afamelanotide (CAS 75921-69-6). Both terms refer to a 13-amino-acid analog of α-MSH that binds melanocortin-1 receptors (MC1R) to stimulate eumelanin production in melanocytes. The MT-1 abbreviation originated in academic research settings, while Melanotan-1 became the commercial and clinical identifier. The compound's international nonproprietary name (INN) is afamelanotide, but MT-1 and Melanotan-1 remain the dominant terms in peptide research communities.

The real question isn't what separates MT-1 from Melanotan-1. It's why the naming persists in parallel. Afamelanotide entered Phase III trials in the early 2000s for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe photosensitivity. The European Medicines Agency approved it in 2014 under the brand name Scenesse. Despite formal INN adoption, the research community retained MT-1 and Melanotan-1 as functional shorthand because these terms predate regulatory naming by nearly two decades. When procuring peptides for research, you'll encounter all three designations. MT-1, Melanotan-1, and afamelanotide. Referencing the same CAS number and amino-acid sequence. This article covers the naming origin, the biological mechanism that makes this peptide distinct from unrelated compounds, and the procurement clarity researchers need when sourcing MT-1 for lab work.

The Naming Timeline: How MT-1 and Melanotan-1 Became Interchangeable

MT-1 originated as laboratory shorthand during peptide synthesis studies conducted at the University of Arizona College of Medicine in 1981. The research team, led by Dr. Norman Levine and Dr. Mac Hadley, synthesised a series of α-MSH analogs to investigate melanogenesis pathways. The first analog in this series. A linear 13-amino-acid peptide with enhanced MC1R affinity. Was catalogued internally as MT-1 (Melanotan-1). The designation stuck. By the time the compound progressed to animal models in 1985, MT-1 had become the dominant identifier in academic publications. Clinical development in the 1990s formalised the name as Melanotan-1 to distinguish it from a structurally different analog, Melanotan-II (MT-2), which contains a lactam bridge and binds multiple melanocortin receptor subtypes. The International Nonproprietary Name (INN) afamelanotide was assigned in 2008, but MT-1 and Melanotan-1 remain prevalent in research contexts because peptide suppliers and academic labs adopted these terms decades earlier.

The persistence of dual naming creates confusion during procurement. Researchers ordering 'MT-1' and 'Melanotan-1' from different suppliers may assume they're comparing formulations when they're ordering the same peptide under different labels. We've seen this cause unnecessary redundancy in lab inventories and experimental design errors when teams don't recognise that published MT-1 studies and Melanotan-1 trials reference identical compounds. Afamelanotide is the formal name, but practical research communication still defaults to MT-1 shorthand.

Mechanism: Why Melanotan-1 (MT-1) Stimulates Melanin Without UV Exposure

Melanotan-1 functions as a melanocortin-1 receptor (MC1R) agonist, mimicking the action of endogenous α-MSH to trigger eumelanin synthesis in dermal melanocytes. Natural tanning occurs when ultraviolet (UV) radiation damages keratinocytes, prompting them to release α-MSH, which binds MC1R on melanocytes and activates adenylate cyclase. This cascade increases cyclic AMP (cAMP) levels, upregulating tyrosinase. The enzyme that converts L-tyrosine into melanin precursors. Melanotan-1 bypasses the UV-damage prerequisite by directly binding MC1R with higher affinity than native α-MSH (approximately 10–50 times greater binding affinity depending on receptor density), initiating melanogenesis without requiring sun exposure.

The critical distinction between UV-induced tanning and Melanotan-1-induced pigmentation is the damage signal. UV tanning is a defensive response to DNA photodamage. Melanin production serves as a biological shield to prevent further mutation. Melanotan-1 activates the same downstream pathway but without the DNA lesions that normally trigger it. Clinical studies in erythropoietic protoporphyria patients demonstrated that subcutaneous afamelanotide (16mg implant delivering sustained release over 60 days) increased melanin density by 150–200% from baseline within four weeks, measured by reflectance spectrophotometry. This pigmentation occurred without concurrent UV exposure, proving that melanin synthesis is dissociable from photodamage when the MC1R pathway is pharmacologically activated. The peptide's linear structure and lack of MC3R/MC4R cross-reactivity (unlike Melanotan-II) means its effects are confined to melanocytes. It does not induce appetite suppression or erectile effects associated with non-selective melanocortin agonists.

MT-1 vs Melanotan-II: The Real Comparison That Matters

The meaningful comparison isn't between MT-1 and Melanotan-1. It's between Melanotan-1 (MT-1) and Melanotan-II (MT-2). These are structurally and pharmacologically distinct peptides. Melanotan-1 is a linear 13-amino-acid sequence (Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val) with selective MC1R affinity. Melanotan-II is a cyclic 7-amino-acid analog with a lactam bridge between positions 4 and 10, conferring non-selective binding to MC1R, MC3R, MC4R, and MC5R. This structural difference produces divergent pharmacological profiles.

Melanotan-1 reached regulatory approval because its MC1R selectivity confined effects to melanocytes, producing predictable pigmentation without systemic complications. Melanotan-II's broader receptor activity introduced variables. Appetite changes, increased libido, potential cardiovascular effects. That complicated clinical development. When researchers reference MT-1, they're discussing a compound with a decade of post-market safety data. MT-2 remains an investigational peptide with no approved formulations.

Key Takeaways

• Melanotan-1 and MT-1 are identical. Both refer to afamelanotide (CAS 75921-69-6), a 13-amino-acid synthetic analog of α-MSH that binds MC1R to stimulate eumelanin production.
• The MT-1 abbreviation originated in 1981 research protocols at the University of Arizona, predating the formal INN designation afamelanotide by 27 years.
• MT-1 stimulates melanogenesis without requiring UV exposure by directly activating melanocortin-1 receptors with 10–50 times the binding affinity of endogenous α-MSH.
• The real comparison is MT-1 vs MT-2. Melanotan-II is a structurally distinct cyclic peptide with non-selective melanocortin receptor binding, producing broader systemic effects including appetite suppression and sexual side effects.
• Afamelanotide (Scenesse) is EMA-approved for erythropoietic protoporphyria, making MT-1 the only melanocortin agonist with regulatory approval and established long-term safety data.
• When sourcing peptides for research, verify the CAS number (75921-69-6). MT-1, Melanotan-1, and afamelanotide all reference the same compound, but supplier labeling varies.

Melanotan-1 vs MT-1: Naming Comparison

What If: Melanotan-1 Scenarios

What If I Ordered MT-1 But Received a Vial Labeled Afamelanotide?

You received the correct compound. Verify the CAS number on the certificate of analysis (CoA) matches 75921-69-6. If it does, the peptide is identical regardless of label terminology. Suppliers use MT-1, Melanotan-1, and afamelanotide interchangeably because all three names reference the same 13-amino-acid sequence. Cross-reference the amino-acid composition on the CoA against the published sequence (Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val) to confirm accuracy. If the molecular weight listed is approximately 1646 Da and the sequence matches, nomenclature differences are irrelevant.

What If My Research Protocol References MT-1 But I Can Only Source Melanotan-1?

Proceed with the Melanotan-1. It's the same peptide. The MT-1 designation appears predominantly in pre-2008 literature before the INN afamelanotide was formalised. When replicating older studies, match the dosing and administration route rather than the label name. If the original protocol specifies 'MT-1 at 0.16 mg/kg subcutaneous', using Melanotan-1 at that dose achieves identical pharmacological results because the molecular structure, receptor binding profile, and half-life are unchanged.

What If I'm Comparing MT-1 Studies to Melanotan-II Research — Are the Mechanisms Transferable?

No. MT-1 and MT-2 activate different receptor sets, producing non-overlapping effects beyond melanogenesis. MT-1 binds selectively to MC1R, limiting activity to dermal melanocytes. MT-2's cyclic structure enables binding to MC3R (appetite regulation), MC4R (energy homeostasis, sexual function), and MC5R (sebaceous gland activity), creating systemic outcomes MT-1 does not produce. Studies demonstrating appetite suppression or erectile effects with MT-2 cannot be extrapolated to MT-1 because those pathways require MC3R/MC4R activation, which MT-1 lacks. When designing experiments, treat MT-1 and MT-2 as functionally distinct compounds despite their shared melanocortin framework.

The Direct Truth About Melanotan-1 and MT-1

Here's the honest answer: there is no functional, structural, or pharmacological difference between Melanotan-1 and MT-1 because they are the same peptide under two names. The confusion persists because peptide nomenclature evolved across three decades. MT-1 was lab shorthand in the 1980s, Melanotan-1 became the clinical identifier in the 1990s, and afamelanotide emerged as the regulatory name in 2008. Anyone telling you MT-1 and Melanotan-1 represent different compounds or formulations is either misinformed or deliberately obfuscating to justify price differences between identically labeled products. The CAS registry number 75921-69-6 resolves this definitively. Every MT-1, Melanotan-1, and afamelanotide product with that CAS contains the same 13-amino-acid sequence synthesised to the same molecular structure.

The distinction that actually matters is between Melanotan-1 (MT-1) and Melanotan-II (MT-2). Those are chemically and pharmacologically distinct analogs with divergent receptor profiles and safety considerations. If you're procuring peptides for melanogenesis research and need MC1R-selective activity without systemic melanocortin effects, verify the supplier is providing the linear 13-amino-acid peptide, not the cyclic 7-amino-acid MT-2 variant. Mislabeling does occur. Particularly in grey-market channels. So demand a certificate of analysis with mass spectrometry confirmation and amino-acid sequencing.

Real Peptides maintains high-purity research-grade peptides with exact amino-acid sequencing verified through independent third-party analysis. Every batch includes a CoA specifying molecular weight, purity percentage, and sequence confirmation. Critical documentation when replicating published MT-1 protocols or designing new melanogenesis studies. If your work requires verified afamelanotide for photoprotection research, explore high-purity research peptides with transparent sourcing and batch traceability.

The naming debate is semantic noise. Focus on the CAS number, the amino-acid sequence, and the certificate of analysis. Those three data points tell you whether you're holding MT-1, Melanotan-1, or afamelanotide. And the answer, in every legitimate case, is the same compound.